Misplaced Pages

Elapegademase, sold under the brand name Revcovi, is a medication for the treatment of the rare disease adenosine deaminase deficiency-SCID in children and adults.

It is a recombinant enzyme that is administered weekly by intramuscular injection.

Elapegademase may interact with PEGylated drugs.

Elapegademase-lvlr was approved by the U.S. Food and Drug Administration (FDA) in 2018. Leadiant Biosciences was awarded a priority review voucher for its development under the pediatric rare diseases program.

References

1. Skidmore-Roth L (2022). "Elapegademase". Mosby's 2023 Nursing Drug Reference. Elsevier Health Sciences. p. 429. ISBN 978-0-323-93330-8.
2. "Elapegademase: Drug Information". www.uptodate.com. Retrieved 28 March 2019.
3. ^ "LexiComp: Elapegademase-lvlr". LexiComp. Retrieved 28 March 2019.
4. "Drug Approval Package: Revcovi". U.S. Food and Drug Administration (FDA). 7 November 2018. Retrieved 26 December 2019.
5. "Elapegademase-lvlr Orphan Drug Designation and Approval". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 26 December 2019.
6. "Drug Trial Snapshot: Revcovi". U.S. Food and Drug Administration (FDA). 5 October 2018. Retrieved 26 December 2019.
7. "Elapegademase - Leadiant Biosciences". AdisInsight. Springer Nature Switzerland AG. Retrieved 28 March 2019.

External links

• "Elapegademase". Drug Information Portal. U.S. National Library of Medicine.

• Medicine

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Enzymes used as drugs
• Orphan drugs
• Antineoplastic and immunomodulating drug stubs